NASDAQ:YMAB - Y-mAbs Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $55.14
  • Forecasted Upside: 92.14 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$28.70
▼ -1.52 (-5.03%)

This chart shows the closing price for YMAB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Y-mAbs Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for YMAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for YMAB

Analyst Price Target is $55.14
▲ +92.14% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Y-mAbs Therapeutics in the last 3 months. The average price target is $55.14, with a high forecast of $68.00 and a low forecast of $45.00. The average price target represents a 92.14% upside from the last price of $28.70.

This chart shows the closing price for YMAB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Y-mAbs Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/4/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/2/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/31/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/31/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/29/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/14/2021HC WainwrightReiterated RatingBuy$68.00Medium
8/9/2021HC WainwrightReiterated RatingBuy$68.00Medium
7/7/2021HC WainwrightReiterated RatingBuy$68.00High
6/28/2021HC WainwrightLower Price TargetBuy$70.00 ➝ $68.00Low
5/7/2021Bank of AmericaUpgradeNeutral ➝ BuyHigh
4/21/2021WedbushLower Price TargetOutperform$67.00 ➝ $52.00High
3/22/2021JPMorgan Chase & Co.Reiterated RatingOverweight$52.00Low
3/1/2021HC WainwrightBoost Price TargetBuy$65.00 ➝ $70.00Low
1/15/2021Bank of AmericaDowngradeBuy ➝ Neutral$56.00High
12/17/2020WedbushBoost Price TargetOutperform$52.00 ➝ $71.00High
12/17/2020BarclaysBoost Price TargetOverweight$55.00 ➝ $65.00High
11/12/2020Morgan StanleyBoost Price TargetEqual Weight$42.00 ➝ $45.00Medium
11/9/2020BarclaysBoost Price TargetPositive ➝ Overweight$47.00 ➝ $53.00Medium
11/9/2020HC WainwrightBoost Price TargetBuy$52.00 ➝ $65.00Medium
10/19/2020Canaccord GenuityReiterated RatingBuy$48.00High
7/15/2020Morgan StanleyBoost Price TargetEqual Weight$39.00 ➝ $42.00High
7/1/2020HC WainwrightReiterated RatingBuy$52.00Low
5/11/2020WedbushBoost Price TargetOutperform$41.00 ➝ $48.00Medium
5/11/2020HC WainwrightBoost Price TargetBuy$41.00 ➝ $52.00Medium
5/4/2020BarclaysInitiated CoverageOverweight$44.00Low
5/1/2020Janney Montgomery ScottInitiated CoverageBuyHigh
4/29/2020Morgan StanleyInitiated CoverageEqual WeightHigh
3/12/2020CowenReiterated RatingBuyHigh
1/28/2020HC WainwrightReiterated RatingBuy$40.00 ➝ $41.00Medium
12/24/2019JPMorgan Chase & Co.Initiated CoverageOverweight$39.00 ➝ $39.00Medium
12/12/2019CowenInitiated CoverageBuyLow
12/12/2019HC WainwrightReiterated RatingBuy$40.00Medium
12/2/2019HC WainwrightReiterated RatingBuy$40.00High
11/27/2019GuggenheimInitiated CoverageBuy$40.00Low
11/19/2019GuggenheimInitiated CoverageBuy$40.00High
11/18/2019HC WainwrightReiterated RatingBuy$40.00Low
11/4/2019HC WainwrightReiterated RatingBuyLow
10/29/2019HC WainwrightBoost Price TargetBuy$43.00Low
10/28/2019CowenReiterated RatingBuyLow
9/3/2019WedbushInitiated CoverageOutperform$38.00Medium
8/26/2019HC WainwrightSet Price TargetBuy$40.00Low
7/1/2019CowenReiterated RatingBuyLow
6/10/2019HC WainwrightReiterated RatingBuy$36.00 ➝ $40.00High
5/28/2019HC WainwrightSet Price TargetBuy$36.00High
4/1/2019HC WainwrightInitiated CoverageBuy ➝ Buy$36.00Medium
10/16/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$26.00High
10/16/2018Canaccord GenuityInitiated CoverageBuy$30.00High
10/16/2018CowenReiterated RatingBuyHigh
10/16/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$35.00High
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/28/2021
  • 7 very positive mentions
  • 5 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
9/27/2021

Current Sentiment

  • 7 very positive mentions
  • 5 positive mentions
  • 6 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Y-mAbs Therapeutics logo
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Read More

Today's Range

Now: $28.70
Low: $28.58
High: $29.78

50 Day Range

MA: $31.55
Low: $27.47
High: $37.31

52 Week Range

Now: $28.70
Low: $24.77
High: $55.22

Volume

111,300 shs

Average Volume

267,603 shs

Market Capitalization

$1.25 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Y-mAbs Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Y-mAbs Therapeutics in the last twelve months: Bank of America Co., Barclays PLC, Canaccord Genuity, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for YMAB.

What is the current price target for Y-mAbs Therapeutics?

7 Wall Street analysts have set twelve-month price targets for Y-mAbs Therapeutics in the last year. Their average twelve-month price target is $55.14, suggesting a possible upside of 92.1%. HC Wainwright has the highest price target set, predicting YMAB will reach $68.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $45.00 for Y-mAbs Therapeutics in the next year.
View the latest price targets for YMAB.

What is the current consensus analyst rating for Y-mAbs Therapeutics?

Y-mAbs Therapeutics currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe YMAB will outperform the market and that investors should add to their positions of Y-mAbs Therapeutics.
View the latest ratings for YMAB.

What other companies compete with Y-mAbs Therapeutics?

How do I contact Y-mAbs Therapeutics' investor relations team?

Y-mAbs Therapeutics' physical mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company's listed phone number is (646) 885-8505 and its investor relations email address is [email protected] The official website for Y-mAbs Therapeutics is www.ymabs.com.